MY208408A - Process for the preparation of a medicament containing an oxepane ring - Google Patents

Process for the preparation of a medicament containing an oxepane ring

Info

Publication number
MY208408A
MY208408A MYPI2022001035A MYPI2022001035A MY208408A MY 208408 A MY208408 A MY 208408A MY PI2022001035 A MYPI2022001035 A MY PI2022001035A MY PI2022001035 A MYPI2022001035 A MY PI2022001035A MY 208408 A MY208408 A MY 208408A
Authority
MY
Malaysia
Prior art keywords
preparation
medicament containing
oxepane ring
oxepane
ring
Prior art date
Application number
MYPI2022001035A
Inventor
Cheng Zhigang
MCCLORY Andrew (Deceased)
Gosselin Francis
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MY208408A publication Critical patent/MY208408A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

A process for the manufacture N-(5-((5R,6S)-5-amino-6-fluorooxepan-2-yl)-1-methyl- 1H-pyrazol-4-yl)-2-(2,6-difluorophenyl)thiazole-4-carboxamide (I) is claimed. [NO SUITABLE FIGURE]
MYPI2022001035A 2019-09-11 2020-09-10 Process for the preparation of a medicament containing an oxepane ring MY208408A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962898861P 2019-09-11 2019-09-11
US201962934382P 2019-11-12 2019-11-12
PCT/US2020/050086 WO2021050654A1 (en) 2019-09-11 2020-09-10 Process for the preparation of a medicament containing an oxepane ring.

Publications (1)

Publication Number Publication Date
MY208408A true MY208408A (en) 2025-05-08

Family

ID=72614037

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2022001035A MY208408A (en) 2019-09-11 2020-09-10 Process for the preparation of a medicament containing an oxepane ring

Country Status (20)

Country Link
US (1) US11414412B2 (en)
EP (1) EP4028396B1 (en)
JP (1) JP7370457B2 (en)
KR (1) KR102786186B1 (en)
CN (1) CN114341134B (en)
AU (1) AU2020345916B2 (en)
BR (1) BR112022004455B1 (en)
CA (1) CA3147844A1 (en)
CL (1) CL2022000581A1 (en)
CR (1) CR20220100A (en)
ES (1) ES2972049T3 (en)
IL (1) IL291174B2 (en)
MX (1) MX2022002962A (en)
MY (1) MY208408A (en)
PE (1) PE20220709A1 (en)
PL (1) PL4028396T3 (en)
SA (1) SA522431923B1 (en)
TW (1) TWI856177B (en)
WO (1) WO2021050654A1 (en)
ZA (1) ZA202202178B (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130296569A1 (en) * 2010-11-03 2013-11-07 Vijaykumar Jagdishwar Patil Process for the preparation of phosphoric acid mono-(1--4-methoxymethyl-piperidin-4-yl) ester
WO2014048939A1 (en) 2012-09-26 2014-04-03 F. Hoffmann-La Roche Ag Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
MX2016012007A (en) * 2014-03-18 2016-12-05 Hoffmann La Roche Oxepan-2-yl-pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use.
SE540295C2 (en) * 2016-12-05 2018-05-29 Glactone Pharma Dev Ab Sulfonamide analogues of galiellalactone

Also Published As

Publication number Publication date
TWI856177B (en) 2024-09-21
SA522431923B1 (en) 2024-04-15
CN114341134B (en) 2024-03-08
ES2972049T3 (en) 2024-06-10
EP4028396A1 (en) 2022-07-20
CN114341134A (en) 2022-04-12
IL291174B2 (en) 2025-04-01
JP7370457B2 (en) 2023-10-27
EP4028396B1 (en) 2024-01-03
AU2020345916B2 (en) 2026-08-13
US11414412B2 (en) 2022-08-16
PL4028396T3 (en) 2024-04-29
JP2022547536A (en) 2022-11-14
TW202116309A (en) 2021-05-01
CL2022000581A1 (en) 2022-10-07
CR20220100A (en) 2022-05-23
US20210070749A1 (en) 2021-03-11
BR112022004455B1 (en) 2024-04-30
BR112022004455A2 (en) 2022-06-14
KR102786186B1 (en) 2025-03-27
IL291174A (en) 2022-05-01
EP4028396C0 (en) 2024-01-03
CA3147844A1 (en) 2021-03-18
MX2022002962A (en) 2022-09-29
PE20220709A1 (en) 2022-05-04
WO2021050654A1 (en) 2021-03-18
IL291174B1 (en) 2024-12-01
AU2020345916A1 (en) 2022-03-03
ZA202202178B (en) 2024-06-26
KR20220047324A (en) 2022-04-15

Similar Documents

Publication Publication Date Title
ZA202206923B (en) New methylquinazolinone derivatives
WO2021250468A8 (en) Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1s)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine
GEAP202415804A (en) 4h-pyrrolo[3,2-c]pyridin-4-one compounds
WO2014188178A9 (en) Polymyxin derivatives and their use in combination therapy together with different antibiotics
WO2021011713A8 (en) Imidazopyrimidines as eed inhibitors and the use thereof
WO2017035353A8 (en) Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders
EP4516353A3 (en) Pharmaceutical compositions comprising (2s)-{(1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide
SG10201907576SA (en) Salts of pi3k inhibitor and processes for their preparation
GEP20257772B (en) Pyrrole compounds
WO2019178191A8 (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glycopyranosidase inhibitors
GEP20217327B (en) Spirocycle compounds and methods of making and using same
EP4249071A3 (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
PH12021552263A1 (en) Macrocyclic compounds as sting agonists
PH12020550756A1 (en) An agent for treating nocturnal pollakiuria
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
MX2024007059A (en) Composition comprising an anti-abeta protofibril antibody and a beta-secretase bace1 inhibitor for the treatment of alzheimer's disease.
IL276311B2 (en) Methyllactam ring compound and pharmaceutical use thereof
CA3156320A1 (en) 2-azaspiro[3.4]octane derivatives as m4 agonists
WO2008133128A1 (en) Fused heterocyclic derivative, pharmaceutical composition comprising the derivative, and use of the composition for medical purposes
PH12021550788A1 (en) New amino-pyrimidonyl-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
ZA202202178B (en) Process for the preparation of a medicament containing an oxepane ring
AU2019296118A8 (en) Isothiazolo(5,4-d)pyrimidine compound as IRAK4 inhibitor
EP4286007A3 (en) Pharmaceutical formulation
PH12022550860A1 (en) 5-oxa-2-azaspiro[3.4]octane derivatives as m4 agonists
EP4335515A3 (en) Crystal forms of (s)-n-[5-[1-(3-ethoxy-4-methoxyphenyl)- 2-(methylsulfonyl)ethyl]-4,6-dioxo-5,6-dihydro-4h-thieno[3,4-c]pyrrole-1 -yl]acetamide